Top Stock Reports for Microsoft, AstraZeneca & BlackRock

Thursday, June 12, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corp. (MSFT), AstraZeneca PLC (AZN) and BlackRock, Inc. (BLK), as well as two micro-cap stocks Taylor Devices, Inc. (TAYD) and Geospace Technologies Corp. (GEOS). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Jobless Claims Warm Up, PPI Cools DownToday's Featured Research ReportsShares of Microsoft have gained +8.5% over the past year against the Zacks Computer - Software industry’s gain of +12.5%. The company capitalizes on AI business momentum and Copilot adoption alongside accelerating Azure cloud infrastructure expansion. Strong Office 365 Commercial demand has been notably propelling Productivity and Business Processes revenue growth. ARPU increases through E5 and M365 Copilot uptake across key segments. Intelligent Cloud revenues advance through Azure AI development and AI Copilot business growth. Strategic execution has been enhancing non-AI services through enterprise customer growth and operational scale improvements. Xbox content and services benefit from robust performance across third-party and first-party content offerings. The Zacks analyst expects that fiscal 2025 net sales will increase 13.7% compared to fiscal 2024. However, elevated operating expenses and Azure investments amid intensifying cloud competition remain concerns for shareholders.(You can read the full research report on Microsoft here >>>)AstraZeneca’s shares have outperformed the Zacks Medical - Biomedical and Genetics industry over the past six months (+13.9% vs. -5.0%). The company has a diverse product portfolio and a global footprint. Its key drugs like Lynparza, Tagrisso, Imfinzi and Fasenra should keep driving revenues. Its pipeline is strong, with pivotal late and mid-stage pipeline data readouts lined up. AstraZeneca has also been engaged in external acquisitions and strategic collaborations to boost its pipeline while investing in geographic areas of high growth. Backed by its new products and pipeline drugs, AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period. However, potentially lower sales of Lynparza and Farxiga in China, the impact of Part D redesign on U.S. oncology and slowing sales of rare disease drugs are expected to hurt the top line in 2025. Ongoing China investigations are also matters of concern.(You can read the full research report on AstraZeneca here >>>)Shares of BlackRock have outperformed the Zacks Financial - Investment Management industry over the past year (+31.2% vs. +18.7%). The company’s inorganic expansion strategy, aimed at boosting its presence in lucrative alternatives and private equity assets, alongside product diversification efforts, will likely aid top-line and assets under management (AUM) growth. The Zacks analyst expects total revenues and AUM to witness a CAGR of 11.8% and 11.2%, respectively, over the next three years. A solid liquidity position and earnings strength will likely keep capital distribution activities sustainable. However, elevated expenses (primarily due to higher general and administration costs and acquisitions) are a headwind. We project expenses to jump 10.9% in 2025. The company’s significant dependence on overseas revenues exposes it to geopolitical tensions, diverse regulatory and economic environments, and exchange rate fluctuations.(You can read the full research report on BlackRock here >>>)Taylor Devices’ shares have underperformed the Zacks Manufacturing - General Industrial industry over the past year (-17.1% vs. +5.3%). This microcap company with market capitalization of $110.55 million have seen total revenue fell 5% amid a 13% decline in U.S. sales, driving net income down 12%. Rising inventory and slower turnover point to execution inefficiencies, while SG&A burdens increased due to elevated stock-based compensation. Receivables rose 29% and billing efficiency weakened.Nevertheless, Taylor Devices demonstrates strong financial resilience with a debt-free balance sheet and $35.4 million in liquidity as of February 2025. A growing backlog of $33.3 million enhances near-term revenue visibility, with 146 open sales orders, indicating higher project value despite fewer long-term deals. International sales surged 61% YoY, especially in Asia, where revenues doubled to 10%, signaling successful geographic diversification. The firm derives 63% of its revenues from long-term contracts, supporting cash flow stability. Industrial sales rose 36% YoY, reducing reliance on cyclical U.S. infrastructure spending.(You can read the full research report on Taylor Devices here >>>)Shares of Geospace Technologies have underperformed the Zacks Electronics - Measuring Instruments industry over the past year (-29.4% vs. +7.3%). This microcap company with market capitalization of $85.68 million is witnessing Energy Solutions which faces sharp revenue declines, weak contract visibility and uncertain PRM monetization. Intelligent Industrial softness and rising operating costs strain margins. With increasing customer concentration and weak cash flows, execution risk remains high. Trading at deep discounts to peers, the stock offers value contingent on Smart Water scale-up and margin recovery. Nevertheless, Geospace is leveraging its Smart Water segment as a key growth driver, with revenue up 47.7% year over year in second-quarter fiscal 2025, now 30.3% of year-to-date sales. Growth is fueled by Hydroconn connector demand, Aquana momentum and the June 2025 launch of AquaLink, which expands its SaaS-like IoT footprint into multi-family markets. A strong, debt-free balance sheet with $19.8 million in cash and $15 million in credit supports strategic R&D and M&A optionality.(You can read the full research report on Geospace Technologies here >>>)Other noteworthy reports we are featuring today include Shopify Inc. (SHOP), 3M Company (MMM) and Verisk Analytics, Inc. (VRSK).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Today's Must ReadAdoption of Cloud & Office 365 Strength Aid Microsoft (MSFT)Key Drugs Aid AstraZeneca (AZN) Sales, Pipeline StrongRising AUM, Buyouts to Support BlackRock (BLK), Costs HighFeatured ReportsGrowing Merchant Base and AI Tools Aid Shopify (SHOP)Per the Zacks Analyst, Shopify benefits from strong tool adoption, AI-driven features, and growing merchant base.Safety and Industrial Segment Aids 3M (MMM) Amid Forex WoesPer the Zacks analyst, 3M will benefit from robust momentum in the Safety and Industrial unit, led by strength in the roofing granules business. However, forex woes remain concerning for the company.Verisk (VRSK) Gains From Acquisitions Amid Rising ExpensesPer the Zacks analyst, buyouts are instrumental to Verisk's growth strategy, as the company buys global firms to improve data and analytical capabilities. Rising expenses pressures the bottom line.Planned Investments, Permian Basin Focus Aid Occidental (OXY)Per the Zacks analyst Occidental's investments to strengthen infrastructure and expansion of Permian Basin operation through acquisition will drive its performance over the long run.Product Innovation Aids William-Sonoma (WSM), Macro Owes AilPer the Zacks analyst, Williams-Sonoma benefits from new product innovation, strategic collaborations, and B2B initiative. However, higher input costs and ongoing tariff pressures are concerning.Strong Adoption of Cologuard Test Aids Exact Sciences (EXAS)The Zacks analyst is impressed with Exact Sciences' continuous significant progress with its Cologuard test. In Q1 2025, screening revenues increased 14%, led by broad-based Cologuard growth.Airxcel Acquisition Aids Thor (THO) Amid Declining BacklogPer the Zacks analyst, the acquisition of Airxcel has strengthened Thor's supply chain. However, declining backlog doesn't bode well for its sales.New UpgradesBill Holdings (BILL) Rides on Strong SMB Business clientelePer the Zacks analyst, Bill is benefiting from an expanding small and medium business clientele, as well as a diversified business model.United Natural Foods (UNFI) Gains on Natural Sales GrowthPer the Zacks analyst, United Natural Foods is benefiting from natural product sales growth. The company's Natural sales grew 12% to $4,160 million in fiscal third-quarter.EverQuote (EVER) Boasts Revenue Growth, Solid Balance SheetPer the Zacks analyst, consumer traffic, quote request volume and innovative advertiser products and services drive EverQuote revenues. Its strong balance sheet enables it to fulfill debt obligations.New DowngradesChevron Hurt by U.S. Government Sanctions on VenezuelaThe Zacks analyst believes that Chevron's possible exit from Venezuela could weigh on the company's long-term cash flows and supply-chain stability.Ciena (CIEN) Plagued by Tariff Challenges & Rising ExpensesPer the Zacks analyst, Ciena expects potential disruptions from new tariffs and retaliatory trade actions, hurting margins and expansions. Incurring high costs to stay competitive pose concern.Shrinking Margins Hurts Steven Madden's (SHOO) ProfitabilityPer the Zacks analyst, Steven Madden's direct-to-consumer gross margin faces pressure from increased promotional activity. The metric declined 180 bps year-over-year to 60.1% in the first quarter.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report BlackRock (BLK): Free Stock Analysis Report Geospace Technologies Corporation (GEOS): Free Stock Analysis Report Taylor Devices, Inc. (TAYD): Get Free ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks